Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc34774005    free
PDF from PMC    free
html from PMC    free
PDF vom PMID34774005 :   free
PDF vom PMID34774005 :   free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Using genetics to understand the role of kidney function in COVID-19: a mendelian randomization study #MMPMID34774005
  • Zhao JV; Schooling CM
  • BMC Nephrol 2021[Nov]; 22 (1): 381 PMID34774005show ga
  • BACKGROUND: Kidney dysfunction occurs in severe COVID-19, and is a predictor of COVID-19 mortality. Whether kidney dysfunction causes severe COVID-19, and hence is a target of intervention, or whether it is a symptom, is unclear because conventional observational studies are open to confounding. To obtain unconfounded estimates, we used Mendelian randomization to examine the role of kidney function in severe COVID-19. METHODS: We used genome-wide significant, uncorrelated genetic variants to predict kidney function, in terms of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), and then assessed whether people with genetically instrumented higher eGFR or lower UACR, an indication of better kidney function, had a lower risk of severe COVID-19 (8779 cases, 1,001,875 controls), using the largest available cohorts with extensive genotyping. For comprehensiveness, we also examined their role in COVID-19 hospitalization (24,274 cases, 2,061,529 controls) and all COVID-19 (1,12,612 cases, 2,474,079 controls). RESULTS: Genetically instrumented higher eGFR was associated with lower risk of severe COVID-19 (odds ratio (OR) 0.90, 95% confidence interval (CI) 0.83, 0.98) but not related to COVID-19 hospitalization or infection. Genetically instrumented UACR was not related to COVID-19. CONCLUSIONS: Kidney function appears to be one of the key targets for severe COVID-19 treatment. Use of available medications to improve kidney function, such as antihypertensives, might be beneficial for COVID-19 treatment, with relevance to drug repositioning.
  • |*Patient Acuity[MESH]
  • |Albuminuria/urine[MESH]
  • |COVID-19/*complications/*genetics[MESH]
  • |Case-Control Studies[MESH]
  • |Creatinine/urine[MESH]
  • |Genetic Variation[MESH]
  • |Genome-Wide Association Study[MESH]
  • |Glomerular Filtration Rate/*genetics[MESH]
  • |Hospitalization[MESH]
  • |Humans[MESH]
  • |Kidney/*physiopathology[MESH]
  • |Mendelian Randomization Analysis[MESH]
  • |Risk Factors[MESH]
  • |SARS-CoV-2[MESH]
  • |Whites/genetics[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    381 1.22 2021